Gene · 56479
KCNQ5: potassium voltage-gated channel subfamily Q member 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNQ5: potassium voltage-gated channel subfamily Q member 5. Genes, record 56479. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/56479
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NR82 | Potassium voltage-gated channel subfamily KQT member 5 | 932 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58749 | Q9NR82 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8971 | Q9NR82 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2263 | Q9NR82 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2263 | Q9NR82 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 8971 | Q9NR82 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 30455 | Q9NR82 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 30455 | Q9NR82 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 30455 | Q9NR82 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65804 | Q9NR82 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 168775 | Q9NR82 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| EZOGABINE | CHEMBL41355 | KCNQ (Kv7) potassium channel opener | OPENER | ChEMBL |
| FLINDOKALNER | CHEMBL266510 | Voltage-gated potassium channel subunit Kv7.5 activator | ACTIVATOR | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
Trials96
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsNIH grants669
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNQ5 papers | Newest fiscal year |
|---|---|---|---|
| R35GM130377 | Ion Channel Transporter Interactions | 11 | 2025 |
| R01NS107671 | Therapeutic small molecule modulation of Kv channels | 8 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| R01HL137094 | Role of KCNQ2 Channels in Control of Breathing | 4 | 2025 |
| P50AA010761 | Alcohol Research Center - Treatment and Implications | 3 | 2025 |
| R01HL122010 | Decrypting Variants of Uncertain Significance in Long-QT Syndrome | 3 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 2 | 2025 |
| P30DK040561 | Boston Area Nutrition Obesity Research Center (NORC) | 2 | 2025 |
| R01DC007664 | Structural Studies of Ion Channel Assembly and Signaling Complexes | 2 | 2025 |
| R01DK107859 | Genetics of chronotype and impact on metabolic disease | 2 | 2025 |
1 to 10 of 669Source NIH's project files
See all 669 nih grantsPapers763
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Kv7 channels as pharmacological targets for central nervous system diseases. | Pharmacol Rev | 2026 | 42772203 | PubTator, text mining | PubMed |
| Genome-wide association study of vitamin D status in diverse ancestry individuals with adjustment for ambient ultraviolet B (UVB) radiation. | Clin Nutr | 2026 | 42570365 | PubTator, text mining | PubMed |
| CRISPR/Cas9-mediated PHOX2B functional knock-out in IMR32 neuroblastoma cells impairs neuronal excitability through dysregulation of ion channels genes. | Front Physiol | 2026 | 42422362 | PubTator, text mining | PubMed |
| Functional screen for subtype specificity of voltage sensor-targeted Kv7 potentiators. | Br J Pharmacol | 2026 | 42271185 | PubTator, text mining | PubMed |
| Potassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies. | Curr Neuropharmacol | 2026 | 42003125 | PubTator, text mining | PubMed |
| Extensive genetic interactions (epistasis) linked to alcohol use disorder in a high-risk population. | Commun Biol | 2026 | 41942605 | PubTator, text mining | PubMed |
| Snapshot on Cell-to-Cell Communication Nanotubes: From Bacteria to Humans. | Biology (Basel) | 2026 | 41892274 | PubTator, text mining | PubMed |
| M2 muscarinic receptor-dependent contractions of airway smooth muscle are mediated by inhibition of Kv7 channels. | Am J Physiol Cell Physiol | 2026 | 41784087 | PubTator, text mining | PubMed |
| Inflammatory mechanisms underlying early Alzheimer's disease pathology: evidence from the aging rhesus macaque brain. | Front Cell Neurosci | 2026 | 41767744 | PubTator, text mining | PubMed |
| Discovery and Evaluation of E0714 as an Antiepileptic Candidate: A Highly Subtype-Selective Kv7 Agonist within the Kv7 Family Designed Based on a Kv7.2-Specific Pocket. | J Med Chem | 2026 | 41711326 | PubTator, text mining | PubMed |
1 to 10 of 763
See all 763 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/56479
GET https://conductscience.org/api/genes/v1/56479/patents?page=2